Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma

Figures & data

Figure 1 Serum PON1 activity in MM patients as compared with controls (117.35 ± 14.6 vs. 205.91 ± 19.32 U/l); mean ± SD.

Figure 2 Serum ARE activity in MM patients as compared with controls (68.79 ± 10.95 vs. 161.34 ± 20.47 kU/l); mean ± SD.

Figure 3 Serum 8-isoprostane in MM patients as compared with controls (68.73 ± 12.83 vs. 48.31 ± 9.9 pg/ml); mean ± SD.

Table 1 Demographic features and biochemical parameters in control subjects and MM patients

Parameter	Patients	Controls	P-value
Age (years)	69 ± 5.0	71 ± 7.0	0.42
Male/female	22/12	22/13	0.87
Hemoglobin (g/dl)	12.75 ± 0.77 (12.48–13.03)	13.94 ± 0.79 (13.66–14.21)	0.005**
Calcium (mg/dl)	9.03 ± 0.33 (8.91–9.14)	8.95 ± 0.22 (8.87–9.03)	0.26
Creatinine (mg/dl)	0.81 ± 0.15 (0.75–0.86)	0.91 ± 0.22 (0.83–0.99)	0.033*
LDL-C (mg/dl)	173.41 ± 17.36 (167.35–179.47)	132.08 ± 15.72 (127.19, 138.06)	0.000***
HDL-C (mg/dl)	38.00 ± 3.52 (36.77–39.23)	52.17 ± 3.72 (49.08–54.52)	0.000***
PON/HDL	3.11 ± 0.48	4.07 ± 0.8	0.000***
ARE/HDL	1.8 ± 0.43	3.1 ± 0.52	0.000***
Beta2-microglobulin (mg/l)	1.70 ± 0.53 (1.52–1.89)	1.69 ± 0.48 (1.52–1.85)	0.88
Total protein (g/dl)	10.34 ± 0.91 (10.02–10.66)	7.11 ± 0.42 (6.97–7.26)	0.000***

Data represent mean ± SD.

*P < 0.05.

**P < 0.01.

***P < 0.001.